![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
Sanofi-Aventis |
---|---|
Information provided by: | Sanofi-Aventis |
ClinicalTrials.gov Identifier: | NCT00325806 |
Primary objective:
Mean values of systolic and diastolic office blood pressure
Secondary objectives:
Total mortality, occurrence of cardio- and cerebrovascular events, change of mean blood pressure (ABPM : Ambulatory Blood Pressure Monitoring) during the observation
Condition | Intervention | Phase |
---|---|---|
Hypertension |
Drug: Ramipril |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Prevention of Hypertension in Patients With High-Normal Blood Pressure With the ACE-Inhibitor Ramipril - a Randomised Prevention Trial of the Germany Hypertension League. (ACE : Angiotensin Converting Enzyme) |
Estimated Enrollment: | 1010 |
Study Start Date: | December 2000 |
Ages Eligible for Study: | 50 Years to 85 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | HOE498_3E03 |
Study First Received: | April 11, 2006 |
Last Updated: | September 11, 2007 |
ClinicalTrials.gov Identifier: | NCT00325806 History of Changes |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
Vascular Diseases Angiotensin-Converting Enzyme Inhibitors Cardiovascular Agents Antihypertensive Agents |
Ramipril Protease Inhibitors Hypertension |
Molecular Mechanisms of Pharmacological Action Therapeutic Uses Vascular Diseases Angiotensin-Converting Enzyme Inhibitors Enzyme Inhibitors Cardiovascular Diseases |
Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions Ramipril Protease Inhibitors Hypertension |